Estrogen receptors in breast and bone

from virtue of remodeling to vileness of metastasis

I. Bado, Zbigniew Gugala, S. A W Fuqua, X. H F Zhang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer–bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.94.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Apr 3 2017

Fingerprint

Bone Remodeling
Estrogen Receptors
Breast
Neoplasm Metastasis
Bone and Bones
Breast Neoplasms
Neoplasms
Tropism
Bone Development
Osteoclasts
Osteoblasts
Oncogenes
Publications
Homeostasis
Morbidity
Mutation
Mortality

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Estrogen receptors in breast and bone : from virtue of remodeling to vileness of metastasis. / Bado, I.; Gugala, Zbigniew; Fuqua, S. A W; Zhang, X. H F.

In: Oncogene, 03.04.2017.

Research output: Contribution to journalArticle

@article{8dac9748232244b28632b259e7bcb6fd,
title = "Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis",
abstract = "Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer–bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.94.",
author = "I. Bado and Zbigniew Gugala and Fuqua, {S. A W} and Zhang, {X. H F}",
year = "2017",
month = "4",
day = "3",
doi = "10.1038/onc.2017.94",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Estrogen receptors in breast and bone

T2 - from virtue of remodeling to vileness of metastasis

AU - Bado, I.

AU - Gugala, Zbigniew

AU - Fuqua, S. A W

AU - Zhang, X. H F

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer–bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.94.

AB - Bone metastasis is a prominent cause of morbidity and mortality in cancer. High rates of bone colonization in breast cancer, especially in the subtype expressing estrogen receptors (ERs), suggest tissue-specific proclivities for metastatic tumor formation. The mechanisms behind this subtype-specific organ-tropism remains largely elusive. Interestingly, as the major driver of ER+ breast cancer, ERs also have important roles in bone development and homeostasis. Thus, any agents targeting ER will also inevitably affect the microenvironment, which involves the osteoblasts and osteoclasts. Yet, how such microenvironmental effects are integrated with direct therapeutic responses of cancer cells remain poorly understood. Recent findings on ER mutations, especially their enrichment in bone metastasis, raised even more provocative questions on the role of ER in cancer–bone interaction. In this review, we evaluate the importance of ERs in bone metastasis and discuss new avenues of investigation for bone metastasis treatment based on current knowledge.Oncogene advance online publication, 3 April 2017; doi:10.1038/onc.2017.94.

UR - http://www.scopus.com/inward/record.url?scp=85016926795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016926795&partnerID=8YFLogxK

U2 - 10.1038/onc.2017.94

DO - 10.1038/onc.2017.94

M3 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -